Company: VCYT
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001384101-25-000110
Chunk: 97

Company: VERACYTE, INC.
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 8
Chunk 97
---
ization183 212 (29)(14)%361 437 (76)(17)%Other expenses332 588 (256)(44)%948 1,186 (238)(20)%Allocations222 132 90 68 %418 253 165 65 %Total$1,749 $1,874 $(125)(7)%$3,171 $4,518 $(1,347)(30)%Cost of biopharmaceutical and other revenue:        Compensation expense$1,652 $2,072 $(420)(20)%$2,892 $3,533 $(641)(18)%License fees and royalties— — — NM— 150 (150)(100)%Depreciation and amortization52 46 6 13 %99 125 (26)(21)%Other expenses1,410 1,225 185 15 %2,407 1,946 461 24 %Allocations458 469 (11)(2)%872 896 (24)(3)%Total$3,572 $3,812 $(240)(6)%$6,270 $6,650 $(380)(6)%Intangible asset amortization - cost of revenue$2,667 $2,909 $(242)(8)%$5,252 $5,824 $(572)(10)%

Cost of testing revenue increased $4.5 million, or 16%, for the three months ended June 30, 2025 compared to the same period in 2024. The increase in cost of testing revenue was due to increased volume in testing, higher staffing to support testing performance and the build out of infrastructure related to current and future growth expectations, primarily related to Decipher Prostate and Afirma tests, partially offset by lab efficiencies.

Cost of testing revenue increased $6.8 million, or 13%, for the six months ended June 30, 2025 compared to the same period in 2024. The increase in cost of testing revenue was due to increased volume in testing, higher staffing to support testing performance and the build out of infrastructure related to current and future growth expectations, primarily related to Decipher Prostate and Afirma tests, partially offset by lab efficiencies.

Cost of product revenue decreased $0.1 million, or 7%, for the three months ended June 30, 2025